{"id":"avelumab-first-line-maintenance","safety":{"commonSideEffects":[{"rate":"30-40","effect":"Fatigue"},{"rate":"25-35","effect":"Infusion-related reactions"},{"rate":"15-25","effect":"Nausea"},{"rate":"2-5","effect":"Immune-mediated pneumonitis"},{"rate":"1-3","effect":"Immune-mediated hepatitis"},{"rate":"10-20","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Avelumab binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, preventing interaction with PD-1 on T cells. This blockade restores T-cell activation, proliferation, and anti-tumor immunity. In first-line maintenance, it sustains immune response after initial chemotherapy to prevent disease progression.","oneSentence":"Avelumab is a human monoclonal antibody that blocks PD-L1, releasing immune cells from tumor-induced suppression to attack cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:30:36.656Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"First-line maintenance treatment of advanced urothelial carcinoma"},{"name":"First-line maintenance treatment of advanced non-small cell lung cancer (NSCLC)"}]},"trialDetails":[{"nctId":"NCT05092958","phase":"PHASE3","title":"Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-03","conditions":"Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma","enrollment":654},{"nctId":"NCT06412848","phase":"","title":"JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2024-05-09","conditions":"Urothelial Carcinoma","enrollment":360},{"nctId":"NCT04848519","phase":"PHASE2","title":"Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2021-05-20","conditions":"Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma","enrollment":6},{"nctId":"NCT05327530","phase":"PHASE2","title":"A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)","status":"ACTIVE_NOT_RECRUITING","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2022-08-17","conditions":"Locally Advanced or Metastatic Urothelial Carcinoma","enrollment":256},{"nctId":"NCT03228667","phase":"PHASE2","title":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2018-12-11","conditions":"Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma","enrollment":40},{"nctId":"NCT07207928","phase":"","title":"Evaluation of Clinical Outcomes, Tolerability, and Costs of Avelumab Maintenance and Pembrolizumab Second-Line Therapy in Advanced Urothelial Cancer.","status":"COMPLETED","sponsor":"Azienda Ospedaliera Universitaria Integrata Verona","startDate":"2024-09-16","conditions":"Urothelial Cancer","enrollment":35},{"nctId":"NCT07224971","phase":"PHASE2","title":"Impact of Circadian Rhythm on Immunotherapy","status":"RECRUITING","sponsor":"Liza Villaruz, MD","startDate":"2025-12-02","conditions":"Advanced/Metastatic NSCLC","enrollment":350},{"nctId":"NCT05366725","phase":"","title":"A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2022-06-29","conditions":"Urothelial Cancer","enrollment":106},{"nctId":"NCT04887831","phase":"PHASE2","title":"Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab","status":"TERMINATED","sponsor":"G1 Therapeutics, Inc.","startDate":"2021-06-04","conditions":"Urothelial Carcinoma, Bladder Cancer, Myelosuppression Adult","enrollment":92},{"nctId":"NCT05431777","phase":"","title":"A Study to Learn About the Study Medicine (Avelumab) in Japanese Patients With Urothelial Carcinoma That Has Spread","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2022-07-19","conditions":"Urothelial Carcinoma","enrollment":79},{"nctId":"NCT06869473","phase":"PHASE2","title":"Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2025-02-20","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC), Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer","enrollment":67},{"nctId":"NCT06820255","phase":"PHASE4","title":"DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2025-01-07","conditions":"Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable, Upper Tract Urothelial Cancer","enrollment":135},{"nctId":"NCT06640725","phase":"PHASE2","title":"Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N","status":"RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2025-01-02","conditions":"Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck","enrollment":70},{"nctId":"NCT05699135","phase":"","title":"A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer","status":"TERMINATED","sponsor":"Pfizer","startDate":"2023-03-09","conditions":"Urinary Bladder Neoplasms, Bladder Cancer, Bladder Tumors","enrollment":150},{"nctId":"NCT02603432","phase":"PHASE3","title":"A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-04-25","conditions":"Urothelial Cancer","enrollment":700},{"nctId":"NCT05700344","phase":"","title":"SOGUG-AVELUMAB_RWD","status":"COMPLETED","sponsor":"Spanish Oncology Genito-Urinary Group","startDate":"2022-09-05","conditions":"Metastatic Urothelial Carcinoma","enrollment":125},{"nctId":"NCT03783936","phase":"PHASE2","title":"Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas","status":"COMPLETED","sponsor":"Ashwin Somasundaram","startDate":"2019-01-24","conditions":"Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Metastasis","enrollment":18},{"nctId":"NCT03774901","phase":"PHASE2","title":"Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2019-03-12","conditions":"Penile Cancer, Penile Neoplasms, Penile Squamous Cell Carcinoma","enrollment":32},{"nctId":"NCT05107427","phase":"PHASE2","title":"Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma","status":"WITHDRAWN","sponsor":"4D pharma plc","startDate":"2022-03-01","conditions":"Urothelial Carcinoma","enrollment":""},{"nctId":"NCT02625610","phase":"PHASE3","title":"Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2015-12-24","conditions":"Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction","enrollment":499},{"nctId":"NCT02938273","phase":"PHASE1","title":"Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2017-02-01","conditions":"Carcinoma, Squamous Cell of Head and Neck","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":41,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Avelumab first-line maintenance","genericName":"Avelumab first-line maintenance","companyName":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","companyId":"fondazione-policlinico-universitario-agostino-gemelli-irccs","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Avelumab is a human monoclonal antibody that blocks PD-L1, releasing immune cells from tumor-induced suppression to attack cancer cells. Used for First-line maintenance treatment of advanced urothelial carcinoma, First-line maintenance treatment of advanced non-small cell lung cancer (NSCLC).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}